On June 5, 2020 Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, reported that management will present a company overview at the following virtual investor conferences (Press release, Ionis Pharmaceuticals, JUN 5, 2020, View Source [SID1234560876]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William Blair 40th Annual Growth Stock Conference on Wednesday, June 10, 2020;
Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020; and
BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020.
The above listed dates are subject to change. Details on presentation times or changes to presentation dates can be found on the Company’s website. Please check www.ionispharma.com for the latest information.

A live webcast of the presentations will be available on the Investors & Media section of the Ionis website. The replays will be available within 48 hours and will be archived for a limited time.

On June 5, 2020 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that it will participate in the upcoming 41st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2020 (Press release, Mirati, JUN 5, 2020, View Source [SID1234560875]). Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer at Mirati will represent the Company during the fireside chat at 1:20 p.m. EDT/ 10:20 a.m. PDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and made available through the "Investors" section of the Mirati website at www.mirati.com. Replays will be made available for 90 days following the event.

On June 5, 2020 Amgen (NASDAQ:AMGN) reported that it will present at the Goldman Sachs 41st Annual Virtual Global Healthcare Conference on Wednesday, June 10, 2020 at 1:20 p.m. ET. Peter H. Griffith, executive vice president and chief financial officer, and David M. Reese, M.D., executive vice president of Research and Development at Amgen will present at the conference (Press release, Amgen, JUN 5, 2020, View Source [SID1234560874]). Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen’s website for at least 90 days following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 5, 2020 Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, reported the closing of its initial public offering of 10,350,000 shares of common stock, which includes the exercise in full by the underwriters of their 30-day option to purchase up to an additional 1,350,000 shares of common stock, at a public offering price of $16.00 per share (Press release, Pliant Therapeutics, JUN 5, 2020, View Source [SID1234560873]). The aggregate gross proceeds to Pliant from the initial public offering were approximately $165.6 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares of common stock were offered by Pliant. The shares began trading on The Nasdaq Global Select Market on June 3, 2020, under the ticker symbol "PLRX."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citigroup, Cowen and Piper Sandler acted as joint book-running managers for the initial public offering. Needham & Company acted as lead manager for the offering.

A registration statement on Form S-1 relating to shares of common stock sold in the initial public offering has been filed with the Securities and Exchange Commission and became effective on June 2, 2020. The initial public offering was made only by means of a final prospectus, copies of which may be obtained, when available, from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at [email protected]; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attn: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On June 5, 2020 As the Annual Oncology Meeting transitions to a virtual program, Physicians’ Education Resource reported that (PER) launched "Oncology NOW," a series of free accredited live and interactive webcasts that delivers expert insights, deeper analysis, and critical updates on a variety of therapeutic areas in oncology and hematology (Press release, Physicians’ Education Resource, JUN 5, 2020, View Source [SID1234560872]). PER is committed to producing immersive digital programming that keeps oncologists connected with the latest developments from the annual oncology meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As the leading go-to resource for continuing medical education (CME), it is our responsibility to provide health care providers with in-depth education adjunct to the Annual Oncology Meeting," said Phil Talamo, president of PER. "Through our innovative online programming, we are hosting 11 cutting-edge virtual satellite symposia through our ‘Oncology NOW’ webcast series, working with world renowned faculty to help translate emerging science and new data to better patient care"

The PER "Oncology Now" webcasts are listed below. Details will be released in the coming weeks about the remaining programs.

"Exploring Future Applications of HER2/3-Targeted Therapies Across Multiple Tumor Types"
"Expert Perspectives in Relapsed/Refractory DLBCL: A Look to the Future of Care"
"Hepatocellular Carcinoma Tumor Board: The Experts Address Novel Regimens and Emerging Sequencing Considerations"
"Integrating the Evidence to Optimize Treatment for Patients With Advanced RCC: An Expert Tumor Board Discussion"
"Medical Crossfire: Novel Applications of Liquid Biopsies Across Cancer Care"
"Medical Crossfire: How Can We Maximize Immuno-Oncology Strategies in Small Cell Lung Cancers?"
"Medical Crossfire: Emerging Applications to Optimize and Individualize AML Treatment"
"The Latest Advances on NEDD8 Inhibition for Treatment of Higher-Risk MDS and Other Hematologic Malignancies"
Accredited by the Accreditation Council for Continuing Medical Education, each webcast is approved for 2.0 AMA PRA Category 1 Credits for physicians.

The "Oncology NOW" webcast series is supported by educational grants from AbbVie, Agios Pharmaceuticals Inc., AstraZeneca, Daiichi Sankyo Inc., Eisai Inc., Exelixis Inc., Foundation Medicine Inc., Genentech Inc., Grail, Guardant Health Inc., Lilly, Merck & Co. Inc., MorphoSys US Inc. and Takeda Oncology.